Datatrial are a technology-focused business with a mature and elegant EDC system. We also offer a compliant document management solution and data storage. Our vision is to offer end-to-end documents to data and to include everything from discovery through to post marketing information in one easy to search environment. Key to this is making our platform accessible, both financially and from a user perspective, to small and mid-size businesses across a number of therapeutic areas or focuses (medical device, diagnostics and therapeutics).
With headquarters in Newcastle upon Tyne, UK and offices in Boston MA and BioHub at Alderley Park, UK we are very able to support global clinical development programs. Since 1999, we have been serving the pharmaceutical community through our commitment to service and quality in every aspect of the work that we do. With involvement in over 300 clinical trials, across 25 therapeutic areas and with extensive oncology experience we will work with you to develop a software solution that best fits your needs.
Ms Amy WrightStrategic Services Manager
Ms Emma BanksCEO
Sygnature Discovery Ltd
Sygnature Discovery is the UK’s largest independent provider of integrated drug discovery resource and expertise. Founded in 2004, Sygnature undertakes complete drug discovery programmes and target validation, hit identification, hit-to-lead and lead optimisation projects for pharmaceutical and biotech companies. Core capabilities include medicinal and synthetic chemistry, in vitro biology/screening, computational chemistry, DMPK and protein crystallography. Sygnature has an enviable track record of success in delivering multiple clinical candidates.
Dr Paul ClewlowSVP, Business Development
SYNthesis med chem, founded in 2007, is a relatively new player in the chemistry CRO market. We are Australian owned with laboratory facilities in Shanghai China and offices in Australia, the US and the UK. The management team at SYNthesis are experienced drug discovery professionals with expertise across a range of targets (particularly Kinases, GPCRs and epigenetic targets).
Our clients are drawn from biotech, big pharma and academia, we have an outstanding client return rate with several clients working with us across two or more target classes.
Mr Simon BuryGlobal Head of Business Development
Mr Tim JoslinSenior Partner
Xplico was established in 2005 with the purpose of develop and market an easy-to-use and standardized tool and processes for valuation of project and portfolios in the life science industry.
Xplico is today the market leader in valuation supporting more than 75 life science companies in US and EU on a day to day basis.
Xplico is headquartered in Copenhagen, Denmark.